Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9915434 | 0.92 | NR1H4 (0.44) | SMN1; SMN2LMNA | |
| SCHEMBL9915493 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNAMEN1KMT2ACYP2C9 | |
| SCHEMBL16747360 | 0.78 | MEN1 (0.41) | SMN1; SMN2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL9915520 | 0.78 | NR1H4 (0.45) | SMN1; SMN2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL14136604 | 0.77 | USP2 (0.45) | SMN1; SMN2CYP2C9HPGDMAPT | |
| SCHEMBL16747452 | 0.76 | PTPRC (0.36) | KDM4EL3MBTL1MAPT | |
| SCHEMBL9915331 | 0.76 | MEN1 (0.40) | LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL14136527 | 0.76 | PPARD (0.43) | SMN1; SMN2LMNACYP2C9HPGDMAPT | |
| SCHEMBL9915302 | 0.75 | TP53 (0.40) | ALDH1A1HPGD | |
| SCHEMBL16747359 | 0.74 | MAPT (0.44) | SMN1; SMN2LMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148326-A1 | Monobactams | PFIZER (US) | 2015-05-28 | — | — | US | disclosed |
| US-20130252935-A1 | Monobactams | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20120302542-A1 | MONOBACTAMS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| WO-2012073138-A1 | MONOBACTAMS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252935-A1 | Monobactams | MGAM, MGAM2, BPGM | SMN1; SMN2 4574/4885LMNA 4489/4885MEN1 2023/4885 |
| US-20150148326-A1 | Monobactams | MGAM, MGAM2, BPGM | SMN1; SMN2 4574/4885LMNA 4489/4885MEN1 2023/4885 |
| US-20120302542-A1 | MONOBACTAMS | MGAM, MGAM2, BPGM | SMN1; SMN2 4574/4885LMNA 4489/4885MEN1 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.